Close Menu

NEW YORK – The US Food and Drug Administration has accepted Kronos Bio's investigational new drug application for its CDK9 inhibitor KB-0742, allowing the firm to begin clinical trials in MYC-amplified advanced solid tumors in the first quarter of 2021.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.